{"prompt": "['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'KEYTRUDA (pembrolizumab) [package insert]. Whitehouse Station (NJ): Merk Sharp &', 'Dohme Corp; 2018.', 'Look KY, Blessing JA, Levenback C, et al. A Phase II Trial of CPT-11 in Recurrent Squamous', 'Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecologic Oncology', '1998;70, 334-338.', 'Long III HJ, Bundy BN, Grendys Jr EC, et al. Randomized Phase III Trial of Cisplatin With or', 'Without Topotecan in Carcinoma of the Uterine Cervix: A Gynecologic Oncology Group Study.', 'J Clin Oncol 2005;23:4626-4633.', 'Lorusso D, Ferrandina G, Pignata S, et al. Evaluation of pemetrexed (Alimta, LY231514) as', 'second-line chemotherapy in persistent or recurrent carcinoma of the cervix: the CERVIX 1', 'study of the MITO (Multicentre Italian Trials in Ovarian Cancer and Gynecologic Malignancies)', 'Group. Ann Oncol 2010; 21.', 'McLachlan J, Boussios S, Okines A, et al. The Impact of Systemic Therapy Beyond First-line', 'Treatment for Advanced Cervical Cancer. Clinical Oncology (2016),', 'http://dx.doi.org/10.1016/j.clon.2016.10.00', 'Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1', 'Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med', '2018; 379(4):341-51.', 'Miller DS, Blessing JA, Bodurka DC, et al. Evaluation of pemetrexed (Alimta, LY231514) as', 'second line therapy in persistent or recurrent carcinoma of the cervix: a phase 2 study of the', 'Gynecologic Oncology Group. Gynecol Oncol 2008; 110:65-70.', 'Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus Everolimus in Advanced', 'Renal-Cell Carcinoma. N Engl J Med 2015;373:1803-13.', 'Muderspach LI, Blessing JA, Levenback C, et al. A Phase II Study of Topotecan in Patients with', 'Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study. Gynecologic', 'Oncology 2001;81, 213-215.', 'Muggia FM, Blessing JA, Method M, et al. Evaluation of vinorelbine in persistent or recurrent', 'squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecologic', 'Oncology 2004;92: 639-643.', 'Muggia FM, Blessing JA, Waggoner S, et al. Evaluation of vinorelbine in persistent or recurrent', 'nonsquamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecologic', 'Oncology 2005;96:108-111.', 'Mutch DG, Orlando M, Goss T, et al. Randomized phase III trial of gemcitabine compared with', 'pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol', '2007;25:2811-2818.', 'Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint', 'antibodies. Annals of Oncology 2015;26: 2375-2391.', 'National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Cervical', 'Cancer. Version 1.2017 - October 10, 2016. NCCN.org.', 'Regeneron Pharmaceuticals, Inc.', 'Page 108 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']['Clinical Study Protocol', 'R2810-ONC-1676 Amendment 7', 'Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in advanced Merkel', 'cell carcinoma. N Engl J Med 2016;374:2542-2552.', 'Nishino M, Ramaiya NH, Awad MM, et al. PD-1 inhibitor-related pneumonitis in advanced', 'cancer patients: Radiographic patterns and clinical course. Clin Cancer Res. 2016 Aug 17. pii:', 'clincanres 1320.2016. [Epub ahead of print].', 'Papadopoulos KP, Crittenden M, Johnson, M, et al. A first-in-human study of REGN2810, a', 'fully human monoclonal antibody against programmed death-1 (PD-1) in combination with', 'immunomodulators including hypofractionated radiotherapy (hfRT). J Clin Oncol', '2016;34:(suppl labstr 3024).', 'Pfisterer J, Plante M, Vergote I, et al. Gemcitabine Plus Carboplatin Compared With Carboplatin', 'in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the', 'AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 2006;24:4699-4707.', 'Rischin D, Gil-Martin M, Gonzalez-Martin A, Brana I, Hou JY, Cho D, et al. 2018. Cemiplimab,', 'a Human PD-1 Monoclonal Antibody, in Patients with Recurrent or Metastatic Cervical Cancer:', 'Interim Data from Phase 1 Cohorts. European Society for Medical Oncology Congress. Munich,', 'Germany.', 'Schilder RJ, Blessing J, Cohn DE. Evaluation of gemcitabine in previously treated patients with', 'non-squamous cell carcinoma of the cervix: a phase II study of the Gynecologic Oncology', 'Group. Gynecol Oncol 2005;96:103-107.', 'Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2016. CA Cancer J Clin. 66:7-30.', 'Takeuchi S, Dobashi K, Fujimoto S, et al. A late phase study of CPT-11 on uterine cervical', 'cancer and ovarian cancer. Research Groups of CPT-11 in Gynecologic Cancers. Gan To', 'Kagaku Ryoho 1991 Aug;18(10):1681-9.', 'Tanioka M, Katsumata N, Yonemori K, et al. Second platinum therapy in patients with uterine', 'cervical cancer previously treated with platinum chemotherapy. Cancer Chemother Pharmacol', '(2011) 68:337-342.', 'ten Bokkel Huinink W, Lane SR, Ross GA, et al. Long-term survival in a phase III, randomised', 'study of topotecan versus paclitaxel in advanced epithelial ovarian carcinoma. Annals of', 'Oncology 2004;15: 100-103.', 'Tewari KS, Sill MW, Monk BJ, et al. Prospective Validation of Pooled Prognostic Factors in', 'Women with Advanced Cervical Cancer Treated with Chemotherapy with/without', 'Bevacizumab: NRG Oncology/GOG Study. Clin Cancer Res 2015; 21(24)', 'Tewari KS, Sill MW, Long HJ, et al. Improved survival with bevacizumab in advanced cervical', 'cancer. N Engl J Med 2014;370:734-743.', 'The Cancer Genome Atlas Research Network. Integrated genomic and molecular', 'characterization of cervical cancer. Nature http://dx.doi.org/10.1038/nature2138 (2017).', 'Tirumani SH, Ramaiya NH, Keraliya A, et al. Radiographic Profiling of Immune-Related', 'Adverse Events in Advanced Melanoma Patients Treated with Ipilimumab. Cancer Immunol Res', '2015 Oct;3(10):1185-92.', 'Regeneron Pharmaceuticals, Inc.', 'Page 109 of 145', 'CONFIDENTIAL', 'VV-RIM-00146791-1.( Approved - 14 Apr 2021 GMT-5:00']\n\n###\n\n", "completion": "END"}